Pomerantz LLP, the New York-based law firm, has announced the filing of a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA), urging investors who suffered losses on their ADMA positions to contact the firm before an approaching legal deadline. The alert, issued June 18, 2026, is directed at shareholders who believe their investment in the biologic company resulted in financial harm.
What a Class Action Lawsuit Means for Investors
A securities class action is a legal mechanism that allows a group of investors who suffered similar losses to sue a company collectively rather than individually. The practical effect: individual shareholders who might lack the resources or standing to pursue litigation on their own can join a consolidated case and share in any eventual settlement or judgment.
For ADMA Biologics shareholders, the Pomerantz filing signals that attorneys believe there may be grounds to hold the company legally accountable for investor losses. The firm is actively soliciting affected investors to come forward, which is standard practice in the early stages of building a plaintiff class.
The Deadline Factor
The phrase "upcoming deadlines" in securities litigation carries specific weight. Class action cases involving publicly traded companies typically operate under lead plaintiff deadlines, court-imposed dates by which investors must formally move to be appointed as lead plaintiff if they want an active role in directing the case. Missing this window does not necessarily bar investors from joining the class, but it can limit their ability to shape the litigation's direction.
Pomerantz LLP has identified Danielle Peyton as the contact for investors seeking to learn more. She can be reached at [email protected] or by phone at 646-581-9980.
What Affected Shareholders Should Do Now
Investors who held ADMA Biologics shares and experienced losses should document their trading history and consult the firm directly to assess whether their circumstances qualify for participation. The source provides no detail on the specific allegations underpinning the lawsuit, the time period covered by the class, or the scale of claimed damages — investors will need to contact Pomerantz LLP directly for that information.
The filing itself does not establish wrongdoing; allegations in a class action complaint are unproven until adjudicated or settled. ADMA Biologics has not been quoted in the announcement.